This article examines the evolution of Indian pharmaceutical manufacturer Cipla toward producing drugs that met the quality standards of European and U.S. regulators. It employs new research in both Cipla's corporate archives and a wide range of oral histories. The article argues that, along with a long-standing corporate culture of self-reliance rooted in nationalism starting from the company's inception in 1935, major factors in Cipla's strategy from the 1960s through the early 2000s included the early adoption and continued use of quality-control technology, along with efforts to create global goodwill for affordable high-quality generic drugs during the HIV/AIDS epidemic of the early 2000s.

本文考察了印度制药商 Cipla 向生产符合欧洲和美国监管机构质量标准的药品的演变。它对 Cipla 的企业档案和广泛的口述历史进行了新的研究。文章认为，除了自 1935 年公司成立以来植根于民族主义的自力更生的长期企业文化外，Cip​​la 从 1960 年代到 2000 年代初战略的主要因素包括早期采用和继续使用质量——控制技术，以及在 2000 年代初艾滋病毒/艾滋病流行期间为负担得起的高质量仿制药创造全球善意的努力。